While biomedical research and development has come a long way in understanding lupus and how to manage it, experts believe they have barely made a dent in this autoimmune disease’s complexity and elusiveness. Many diseases stem from and degrade specific organs, which leads to tell-tale symptoms. Lupus, however, tends to…
Australian pharmaceutical giant Invion Limited, recently completed its phase II clinical study on INV103 (ala-Cpn10) in patients with systemic lupus erythematosus (SLE). The study was designed to test the biochemical properties of the drug in escalating doses, administered to patients with SLE and other autoimmune disorders, in considerably higher numbers…
A new study led by researchers at the Henry Ford Hospital in Detroit reported a case of systemic lupus erythematosus (SLE) linked to stroke-like symptoms. The study is entitled “Embolic Stroke as the Initial Manifestation of Systemic Lupus Erythematosus” and was published in the journal…
Results from a Phase 2a clinical trial recently presented during the European League Against Rheumatism Annual European Congress of Rheumatology revealed regional differences in the response to sifalimumab treatment in systemic lupus erythematosus (SLE) patients. Sifalimumab (formerly MEDI-545) is an investigational human monoclonal antibody that targets IFN-α, a type of inflammatory cytokine in…
A team led by researchers at The University of Texas MD Anderson Cancer Center recently revealed new insights into the mechanisms underlying the development of autoimmunity in animal models of systemic lupus erythematosus (SLE). The study was recently published in the journal Cell Reports and is…
Results from a phase 2 clinical trial recently published in the journal Lupus Science and Medicine revealed that edratide (hCDR1, Teva) is effective and has high tolerability in patients with a diagnosis of systemic lupus erythematosus (SLE). However, the study failed to meet its primary endpoints.
In a new study entitled “Bortezomib Plus Continuous B Cell Depletion Results in Sustained Plasma Cell Depletion and Amelioration of Lupus Nephritis in NZB/W F1 Mice” researchers revealed a potential new therapy against the root-cause of systemic lupus erythematosus. The study was published in the journal…
In a new study entitled “Epithelial-to-mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis“ a team of scientists showed that upon injury, kidney cells activate a cellular process, the epithelial-to-mesenchymal transition (EMT), which ultimately leads to fibrosis in the kidneys. The research team performed…
Results from a recent study presented at the European League Against Rheumatism Annual European Congress of Rheumatology showed that patients with lupus nephritis (LN) who are positive for anti-Sm antibodies may be more likely to require immunosuppressive therapy. Lupus nephritis (LN) is kidney inflammation caused by systemic lupus erythematosus (SLE…
Sandra C. Raymond, President and CEO of the Lupus Foundation of America recently participated in a briefing for U.S. Senate staff discussing off-label uses of medications for treating lupus and the importance of physicians having vital information about the impact these off-label medications may have on lupus patients. Lupus…